The World Health Organisation (WHO) has warned that the Ebola strain confirmed in Nigeria has no licensed vaccine or approved specific treatment, placing greater emphasis on early diagnosis, supportive medical care and effective containment measures.
The warning follows Nigeria’s confirmation of an infection caused by the Bundibugyo virus, a strain linked to the ongoing outbreak in the Democratic Republic of the Congo (DRC) and other parts of Africa.
The development presents a significant challenge for health authorities as they work to prevent further transmission, identify exposed individuals and strengthen emergency preparedness across the country.
The WHO explained that, unlike the Zaire strain of Ebola, for which an approved vaccine and specific treatments are available, the Bundibugyo strain currently has no licensed vaccine or approved targeted therapy. Research into potential vaccines and treatments is ongoing.
The absence of approved strain-specific medical countermeasures makes early detection, prompt isolation and quality supportive care particularly important. Medical teams can manage symptoms and complications, including dehydration and organ dysfunction, even though there is no approved treatment specifically targeting the virus.
Nigeria’s confirmed case involves a woman who travelled from Uganda to Abuja and later tested positive for the infection. Laboratory investigations by the Nigeria Centre for Disease Control and Prevention (NCDC) established that the virus was the Bundibugyo strain.
Health authorities have identified 44 contacts linked to the patient for monitoring, while investigations continue to establish the circumstances surrounding the infection and identify anyone else who may have been exposed.
The NCDC and other relevant agencies are strengthening surveillance, contact tracing and infection prevention measures, particularly in healthcare facilities where suspected cases could present for treatment.
One of the challenges associated with Bundibugyo virus disease is that its early symptoms can resemble those of other illnesses, including malaria. The WHO has stressed that laboratory testing is essential to confirming suspected cases, making clinical vigilance and prompt reporting crucial.
The organisation has also highlighted the importance of community cooperation in controlling the outbreak. Public health authorities need residents to report possible exposure, follow medical instructions and avoid direct contact with the bodily fluids of infected people.
Although an approved vaccine specifically for the Bundibugyo strain is unavailable, researchers are evaluating candidate vaccines and investigational treatments. The WHO has also indicated that the existing Ebola vaccine should be assessed within research protocols to determine whether it offers protection against this strain.
Nigeria is drawing on its experience containing the 2014 Ebola outbreak as it strengthens its current response. Federal and state health agencies are working to improve surveillance, coordinate emergency operations and prevent the infection from spreading further.
The immediate priority remains identifying potential cases quickly, monitoring contacts throughout the incubation period and ensuring that suspected patients receive timely medical attention.
The WHO has urged affected and at-risk countries to sustain surveillance, strengthen cross-border cooperation and keep communities informed, stressing that rapid public health action remains central to containing the outbreak.